Currently, anti-tumor immunity through immune checkpoint inhibitors, specifically anti PD-1/PD-L1 interaction, is a new line of treatment for patients with CRC, especially for those at later stages of cancer [27]. This evidence concerns the gene PDCD1 and colorectal carcinoma.